Ngalaba Mba Nile

Na mbido Maachị, National Medical Products Administration kwadoro Jaypirca® (pirtobrutinib) maka ọgwụgwọ nke ndị okenye nwere ọrịa leukemia lymphocytic na-adịghị ala ala (CLL) ma ọ bụ obere lymphocytic lymphoma (SLL) bụ ndị natara ma ọ dịkarịa ala otu ọgwụgwọ sistemu gara aga, gụnyere Bruton's tyrosin...GỤKWUO»

Akụkọ na-atọ ụtọ apụtala n'oge na-adịbeghị anya site na Center for Drug Evaluation (CDE) nke National Medical Products Administration nke China: a kwadola nnwale ahụike maka ọgwụ KSD-101 Injection, nke Hensen Bio mepụtara. Ojiji a tụrụ aro bụ maka "ọrịa ọbara na-akpata EBV nke nwere...GỤKWUO»

N'oge na-adịbeghị anya, China National Medical Products Administration (NMPA) kwadoro ihe ngosi ọhụrụ maka Bireocliclib, ọgwụ ọhụrụ Klas 1 nke Xuanzhu Biopharmaceutical mepụtara n'onwe ya. Ihe ngosi ọhụrụ a bụ maka iji ya na ọgwụ na-egbochi aromatase dị ka ọgwụgwọ endocrine mbụ maka...GỤKWUO»

Na Febụwarị 28, 2026, National Medical Products Administration (NMPA) kwadoro ahịa nke JMKX001899 sulfate maka ọgwụgwọ nke ndị ọrịa toro eto nwere KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) bụ ndị natara ma ọ dịkarịa ala otu ọgwụgwọ sistemu gara aga. JMKX00189...GỤKWUO»

Na Febụwarị 13, 2026, Center for Drug Evaluation (CDE) nke National Medical Products Administration nke China kwupụtara na etinyerela mbadamba GFH375 na Breakthrough Therapy Nhọpụta maka ọgwụgwọ ndị ọrịa nwere KRAS G12D-mutant non-small cell lung cancer (NSCLC) bụ ndị ...GỤKWUO»

Na Febụwarị 12, 2026, Center for Drug Evaluation (CDE) nke National Medical Products Administration nke China kwupụtara na Febụwarị 4 na a tụrụ aro ka etinye ENHERTU® (trastuzumab deruxtecan) na Mmemme Ọgwụgwọ Breakthrough maka iji dị ka ọgwụgwọ mgbakwunye na ndị okenye nwere HER2...GỤKWUO»

Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region nwere obi ụtọ inye ndị ọrịa mba ụwa ohere ịnweta ọgwụgwọ kansa kachasị ọhụrụ, gụnyere Boron Neutron Capture Therapy (BNCT) - ọgwụgwọ mgbanwe nke agbanweela ndụ. Ihe akaebe nke ndụ n'ezie: Njem Oriakụ Wu na 2022...GỤKWUO»

Na Febụwarị 9, 2026, ebe nrụọrụ weebụ gọọmentị nke Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na a na-eme atụmatụ inye ZL-1310 maka ịgba ọgwụ, otu ọhụrụ DLL3-targeting antibody-drug conjugate (ADC), aha Breakthrough Therapy. Dịka onye otu...GỤKWUO»

Maka onye ọrịa ọ bụla na-eme njem dị anya iji chọọ nlekọta anyị, anyị ghọtara nke ọma: ihe ị na-eweta abụghị naanị ndekọ ahụike dị mgbagwoju anya kamakwa ntụkwasị obi na olileanya nke ezinụlọ gị dum. Na Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region, anyị na-ahụ akụkọ ndị dị otú ahụ kwa ụbọchị—ho...GỤKWUO»

N'ịnagide ihe ịma aka ọgwụgwọ nke ọrịa kansa eriri afọ nke HER2, anyị ghọtara nke ọma ọchịchọ gị dị ngwa maka nhọrọ ọgwụgwọ dị irè na nke dị elu. Taa, anyị na-eweta akụkọ na-agba ume sitere na ngalaba oncology nke China. **Ọgwụgwọ Pụrụ Iche Dị Nso: SHR-A1811 Gosiri Pụrụ Iche...GỤKWUO»

N'oge na-adịbeghị anya, Ngalaba Ọgwụ Ahụike Mba nke China kwadoro ọgwụgwọ njikọta nke Anlotinib Hydrochloride na Penpulimab nke Chia Tai Tianqing nyere maka ọgwụgwọ mbụ nke kansa imeju dị elu. Nke a bụ ihe ngosi nke iri akwadoro maka Anlotinib Hyd...GỤKWUO»

N'oge na-adịbeghị anya, ngalaba ọgwụgwọ ọrịa kansa na China enwetala nnukwu ihe ịga nke ọma. Na Jenụwarị 7, 2025, National Medical Products Administration kwadoro ọgwụ ọhụrụ SHR-1701 maka ojiji ahịa. A na-egosi ya yana chemotherapy dị ka ọgwụgwọ mbụ maka l...GỤKWUO»